CN101022792A - 新化合物、包含该化合物的药物组合物及该化合物的应用方法 - Google Patents

新化合物、包含该化合物的药物组合物及该化合物的应用方法 Download PDF

Info

Publication number
CN101022792A
CN101022792A CNA2005800233119A CN200580023311A CN101022792A CN 101022792 A CN101022792 A CN 101022792A CN A2005800233119 A CNA2005800233119 A CN A2005800233119A CN 200580023311 A CN200580023311 A CN 200580023311A CN 101022792 A CN101022792 A CN 101022792A
Authority
CN
China
Prior art keywords
chemical compound
alkyl
aryl
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800233119A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·斯图尔蒂万特
C·A·汤森
S·M·迈德加尔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Fasgen LLC
Original Assignee
Johns Hopkins University
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Fasgen LLC filed Critical Johns Hopkins University
Publication of CN101022792A publication Critical patent/CN101022792A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800233119A 2004-05-26 2005-05-25 新化合物、包含该化合物的药物组合物及该化合物的应用方法 Pending CN101022792A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57463904P 2004-05-26 2004-05-26
US60/574,639 2004-05-26

Publications (1)

Publication Number Publication Date
CN101022792A true CN101022792A (zh) 2007-08-22

Family

ID=35463277

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800233119A Pending CN101022792A (zh) 2004-05-26 2005-05-25 新化合物、包含该化合物的药物组合物及该化合物的应用方法

Country Status (13)

Country Link
US (1) US20090005435A1 (https=)
EP (1) EP1758577A4 (https=)
JP (1) JP2008500363A (https=)
KR (1) KR20070095754A (https=)
CN (1) CN101022792A (https=)
AU (1) AU2005249437A1 (https=)
BR (1) BRPI0510397A (https=)
CA (1) CA2568639A1 (https=)
IL (1) IL179530A0 (https=)
MX (1) MXPA06013687A (https=)
RU (1) RU2006146051A (https=)
WO (1) WO2005117590A2 (https=)
ZA (1) ZA200700024B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
JP5489333B2 (ja) * 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
ES2660690T3 (es) * 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
JP6285442B2 (ja) * 2012-09-07 2018-02-28 ヤンセン ファーマシューティカ エヌ．ベー． がん治療用の脂肪酸合成酵素（ｆａｓｎ）阻害剤として有用なイミダゾリン−５−オン誘導体
WO2016079317A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
MX2022009078A (es) 2020-01-23 2022-08-15 Basf Se Formulaciones de ppo que contienen sulfatos de eter.
JP2023547434A (ja) 2020-10-27 2023-11-10 ビーエーエスエフ ソシエタス・ヨーロピア 有害生物防除用マイクロエマルジョン組成物
CR20230380A (es) 2021-02-05 2023-10-12 Basf Se Composiciones herbicidas liquidas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427847A1 (de) * 1983-12-09 1985-06-13 Bayer Ag, 5090 Leverkusen Thiolan-2,4-dion-3-carboxamide
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
EP1471906A4 (en) * 2002-02-08 2006-02-01 Univ Johns Hopkins Med STIMULATION OF CPT-1 TO REDUCE BODY WEIGHT
EP2386551A1 (en) * 2002-07-09 2011-11-16 Fasgen Inc. Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
IL179530A0 (en) 2007-05-15
WO2005117590A2 (en) 2005-12-15
ZA200700024B (en) 2008-06-25
JP2008500363A (ja) 2008-01-10
BRPI0510397A (pt) 2007-11-13
AU2005249437A1 (en) 2005-12-15
RU2006146051A (ru) 2008-07-10
EP1758577A4 (en) 2010-05-05
EP1758577A2 (en) 2007-03-07
US20090005435A1 (en) 2009-01-01
KR20070095754A (ko) 2007-10-01
WO2005117590A3 (en) 2006-07-27
CA2568639A1 (en) 2005-12-15
MXPA06013687A (es) 2007-10-18

Similar Documents

Publication Publication Date Title
He et al. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
US5614551A (en) Inhibitors of fatty acid synthesis as antimicrobial agents
JP2005533835A (ja) 新規の化合物、それを含有する医薬組成物、およびその使用方法
KR20050072670A (ko) 신규 화합물, 이를 함유하는 약제학적 조성물 및 이의사용방법
CN101022792A (zh) 新化合物、包含该化合物的药物组合物及该化合物的应用方法
CA2617659C (en) Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection
CN1443085B (zh) 发现适于肥胖症治疗和/或预防的化合物的方法
CN109562118A (zh) 非口服给药用医药组合物
Sundaresan et al. Synthesis, characterization and biological evaluations of some novel cyanoacetyl hydrazone derivatives
CN114246876B (zh) 番泻苷a在制备抗铜绿假单胞菌感染的制剂中的用途
CN114890882B (zh) 柏木醇衍生物、其制备方法及其应用
CN102579427A (zh) 合成的内酯制剂及其使用方法
CN116832036A (zh) 一种Erysotrine化合物及其衍生物的应用
US20100029752A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1112837A (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1086485B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029761A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
Abbasi et al. Synthesis, Antibacterial and Lipoxygenase Inhibition Studies of N-(Alkyl/aralkyl)-N-(2, 3-dihydro-1, 4-benzodioxin-6-yl)-4-methylbenzenesulfonamides
CN120771147A (zh) 一种吡唑化合物及其衍生物的应用
CN103555698B (zh) 一种复合凝乳酶的提取工艺
CN105777505A (zh) 一种新型氟代ptp1b抑制剂及其合成和应用
HK1057499B (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
CN104610224A (zh) 一类卤代苯基噻吩酰胺类双靶点抑制剂及其用途
CN104610223A (zh) 一类噻吩酰胺甲苯类sglt2/sglt1双靶点抑制剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1112837

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070822

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1112837

Country of ref document: HK